157 related articles for article (PubMed ID: 37421211)
21. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
[TBL] [Abstract][Full Text] [Related]
22. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.
Tortora F; Negro A; Grasso LFS; Colao A; Pivonello R; Splendiani A; Brunese L; Caranci F
Gland Surg; 2019 Sep; 8(Suppl 3):S150-S158. PubMed ID: 31559182
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
[TBL] [Abstract][Full Text] [Related]
24. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
25. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
[TBL] [Abstract][Full Text] [Related]
26. Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up.
Urbani C; Dassie F; Zampetti B; Mioni R; Maffei P; Cozzi R; Bogazzi F
J Endocrinol Invest; 2024 Jul; 47(7):1733-1741. PubMed ID: 38244140
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
[TBL] [Abstract][Full Text] [Related]
30. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
Shimon I; Saeger W; Wildemberg LE; Gadelha MR
Hormones (Athens); 2017 Jan; 16(1):84-91. PubMed ID: 28500831
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
33. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
34. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
35. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
36. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
37. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
38. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
39. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
40. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
